Evidence map›Paper›PMID 35772597›Full record

SynthesisThe Journal of allergy and clinical immunology2022

Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

Ayobami Akenroye, Grace Lassiter, John W Jackson, Corinne Keet, Jodi Segal, G Caleb Alexander, Hwanhee Hong

Open access · greenAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Journal of allergy and clinical immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 8 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 8 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Comment on 'A Real-World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma'.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Ayobami AkenroyeDivision of Allergy and Clinical Immunology Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md. Electronic address: aakenroye@bwh.harvard.edu.
Grace LassiterGeorgetown College of Medicine, Washington, DC.
John W JacksonDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.
Corinne KeetDivision of Pediatric Allergy and Immunology, University of North Carolina, Chapel Hill, NC.
Jodi SegalDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.
G Caleb AlexanderDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.
Hwanhee HongDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC.
Johns Hopkins University · USBrigham and Women's Hospital · USDuke University · USGeorgetown College · USUniversity of North Carolina at Chapel Hill · US

Funding

NHLBI Training Program in PharmacoepidemiologyT32HL139426 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI G. Caleb Alexander, JODI B. SEGAL · 2018 to 2026
$2.5M
Synthesizing Trial and Real-world Data on the Use of Biologics in Patients with Severe AsthmaR00MD015767 · NIMHD · BRIGHAM AND WOMEN'S HOSPITAL · PI AKENROYE, AYOBAMI T · 2023 to 2025
$677k
Synthesizing Trial and Real-world Data on the Use of Biologics in Patients with Severe AsthmaK99MD015767 · NIMHD · JOHNS HOPKINS UNIVERSITY · PI AKENROYE, AYOBAMI T · 2021 to 2022
$196k
NHLBI NIH HHS T32 HL139426NIMHD NIH HHS K99 MD015767NIMHD NIH HHS R00 MD015767
6 · The paper itself

Abstract

backgroundThe comparative safety and efficacy of the biologics currently approved for asthma are unclear.

objectiveWe compared the safety and efficacy of mepolizumab, benralizumab, and dupilumab in individuals with severe eosinophilic asthma.

methodsWe performed a systematic review of peer-reviewed literature published 2000 to 2021. We studied Bayesian network meta-analyses of exacerbation rates, prebronchodilator FEV

resultsEight randomized clinical trials (n = 6461) were identified. We found in individuals with eosinophils ≥300 cells/μL the following: in reducing exacerbation rates compared to placebo: dupilumab (risk ratio [RR], 0.32; 95% credible interval [CI], 0.23 to 0.45), mepolizumab (RR, 0.37; 95% CI, 0.30 to 0.45), and benralizumab (RR, 0.49; 95% CI, 0.43 to 0.55); in improving FEV

conclusionThere are minimal differences in the efficacy and safety of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma.

Indexed as

Anti-Asthmatic AgentsAsthmaPulmonary EosinophiliaAntibodies, Monoclonal, HumanizedBayes TheoremEosinophilsHumansAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedbenralizumabmepolizumabAsthmaBayesianbenralizumabcomparative effectivenessdupilumabeosinophilicmepolizumabmonoclonal antibodynetwork meta-analysis

Identifiers

PMID35772597
PMCPMC9643621
OpenAlexW4283767956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.